StockNews.AI
TLTFF
StockNews.AI
187 days

CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes

1. Theralase validates RuvidarTM's safety and effectiveness against HSV-1. 2. Previous research from University of Manitoba confirmed in animal model.

2m saved
Insight
Article

FAQ

Why Bullish?

The validation of RuvidarTM enhances Theralase's credibility and potential market impact, similar to past drug approvals boosting stock value.

How important is it?

The validation could significantly impact Theralase's future performance and exploratory investment in herpes treatment.

Why Long Term?

Successful validation can lead to future drug developments and market presence, like other biotech companies gaining value after announcements.

Related Companies

TLTTLTFF
This Press Release updates numerical list in reference section Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ACCESS Newswire / February 13, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the previous University of Manitoba research has now been validated, proving that RuvidarTM is safe and effective in the inactivation of Herpes Simplex Virus, Type 1 ("HSV-1") in an animal model.

Related News